Not finding it? Sign in to also search OpenAlex live.
-
Abstract CT286: TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab vs pembrolizumab alone in treatment-naive unresectable or metastatic melanoma
Sajeve Samuel Thomas, Young Ki Hong, Yazan Samhouri, James Larkin, Gino Kim In, Victoria G. Atkinson, +21 more
2citations -
IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation2023 Journal for ImmunoTherapy of Cancer article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Elisa A. Rozeman, Judith M. Versluis, Karolina Sikorska, Esmée P. Hoefsmit, Petros Dimitriadis, Disha Rao, +15 more
17citations -
Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective
Geeske F. Grit, Esmée van Geffen, Ruben Malmberg, Roelof van Leeuwen, Stefan Böhringer, Hans J.M. Smit, +11 more
18citations -
Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study2025 Journal for ImmunoTherapy of Cancer article Medicine Cancer Immunotherapy and Biomarkers Open access
Michiel M. Smeenk, Vincent van der Noort, Jeroen J. M. A. Hendrikx, Hanieh Abedian Kalkhoran, Egbert Frederik Smit, Willemijn S.M.E. Theelen
12citations -
Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab – the randomized phase 2 FOCUS trial
Anna Paula Brandt, Christoph Schultheiß, Konrad Friedrich Klinghammer, Philippe Schafhausen, Chia‐Jung Busch, Markus Blaurock, +8 more
11citations -
Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Birgit S. Geurts, Laurien Joanna Zeverijn, Lindsay V.M. Leek, Jade M. van Berge Henegouwen, Louisa Rose Hoes, Hanneke van der Wijngaart, +15 more
4citations -
UV1 cancer vaccine in pembrolizumab-treated patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma: results from the randomized phase 2 FOCUS trial
Anna Paula Brandt, Konrad Friedrich Klinghammer, Christoph Schultheiß, Lisa Paschold, Claudia Wickenhauser, Marcus Bauer, +17 more
1citations -
First-line pembrolizumab in metastatic non-small cell lung cancer: A clinical text-mining analysis of effectiveness, costs, and trial eligibility2026 International Journal of Lung Cancer article Medicine Lung Cancer Treatments and Mutations Open access
Hanieh Abedian Kalkhoran, Hedwig M. Blommestein, Henk‐Jan Guchelaar, Egbert F. Smit, Henk Codrington, Loes E. Visser, +1 more
0citations -
Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers2025 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Cancer-related gene regulation Open access
M.M. Gounder, Patricia Martín-Romano, Antoîne Italiano, L. L. Siu, Philippe Alexandre Cassier, Gerald Steven Falchook, +15 more
17citations -
APOLLO: neo-adjuvant pembrolizumab for primary vulvar squamous cell carcinoma—a multicenter, single-arm, phase II, clinical proof-of-concept study2024 International Journal of Gynecological Cancer article Medicine Genital Health and Disease Open access
Mariëtte I.E. van Poelgeest, Kim E. Kortekaas, Helena C. van Doorn, Maaike H.M. Oonk, Hans W. Nijman, Ingrid A Boere, +8 more
3citations -
778 TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy combined with pembrolizumab (pembro) vs pembro alone in treatment-naïve unresectable or metastatic melanoma2023 Regular and Young Investigator Award Abstracts conference-abstract Medicine Cancer Immunotherapy and Biomarkers Open access cited by 2 patents
Daniel J. Olson, James Larkin, Young Ki Hong, Sajeve Samuel Thomas, Juan Martín-Liberal, Andrew J.S. Furness, +13 more
3citations -
KEYMAKER-U01J: Calderasib plus pembrolizumab with or without cetuximab as first-line treatment for advanced or metastatic nonsquamous non–small-cell lung cancer (NSCLC) with KRAS G12C mutations.2026 Journal of Clinical Oncology conference-abstract Medicine Lung Cancer Treatments and Mutations Open access
Qing Zhou, Daniel Almquist, B K Cho, Egbert Frederik Smit, Christian Caglevic, Ilkka Liikanen, +13 more
0citations -
Response to: Comment on ’Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ by Zhu2025 Journal for ImmunoTherapy of Cancer article Medicine Cancer Immunotherapy and Biomarkers Open access
Michiel M. Smeenk, Vincent van der Noort, Jeroen J. M. A. Hendrikx, Hanieh Abedian Kalkhoran, Egbert Frederik Smit, Willemijn S.M.E. Theelen
0citations -
PEMBROLIZUMAB VS PLACEBO PLUS PACLITAXEL ± BEVACIZUMAB FOR PLATINUM-RESISTANT RECURRENT OVARIAN CANCER: RESULTS FROM THE PHASE 3 ENGOT-OV65/KEYNOTE-B96 STUDY2025 International Journal of Gynecological Cancer article Medicine Ovarian cancer diagnosis and treatment
Nicoletta Colombo, Emese Zsíros, Alexandra Sebastianelli, Mariusz Bidziński, Carlos Gallardo, Emad Matanes, +14 more
3citations -
Positionspapier der IAG-KHT zur strukturellen und inhaltlichen Umsetzung der perioperativen Immuntherapie mit Pembrolizumab bei fortgeschrittenen Plattenepithelkarzinomen des Kopf-Hals-Bereichs in Deutschland
Andreas Dietz, Mareike Tometten, Sebastian Ochsenreither, Konrad Friedrich Klinghammer, Jens Peter Klußmann, Thomas Karl Hoffmann, +8 more
2citations